retatrutide update october 2025 Weight Loss as Platform: and the Governance of Multi-Indication Value Demand for Unapproved Weight-Loss Drug

Depends on per-session amount and sessions per month

In September 2025, the FDA issued more than 50 warning letters to companies compounding or marketing GLP-1 products including semaglutide, tirzepatide, and retatrutide

When deciding which weight loss medication, GLP-1 injection or GLP-1 pill is right for you, it's important to consider the average weight loss, side effects and obesity-related conditions

For people with T2D, a phase 2 trial with mazdutide (doses 3, 4.5 and 6 mg) has shown reduction in HbA1c (up to 1.7%) and up to 7.1% WL at 20 weeks (Table 3), while early phase trials for MASH are in progress [72]